Celesq® Programs

Dura Pharmaceuticals Two Years Later: The Continuing Struggle to Define Loss Causation in Securities Fraud Actions

Program Number
Program Date

Tom Gorman reviews the Supreme Court's decision in Dura Pharmaceuticals, which defined loss causation in securities damage actions under Section 10(b) and Rule 10b-5 of the Exchange Act, and focuses on recent key circuit and district court decisions.

Available in States

  • Arizona
  • California
  • Colorado Eligible
  • Georgia
  • Missouri
  • New York
  • Texas Self Study
  • New Jersey Eligible

Program Categories

  • California Participatory MCLE Programs
  • Corporate and Commercial Law
  • In-House Counsel
  • Litigation & Litigation Skills
  • New York Accredited
  • Securities & Investing